{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:08:03Z","timestamp":1778742483541,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020332","name":"Dow University of Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128643","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:39:47Z","timestamp":1777513187000},"page":"128643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenicity and safety of Sabin-strain inactivated poliovirus vaccine in infants: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"83","author":[{"given":"Muhammad","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Athar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saifullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Tayyab","family":"Azam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diya","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javeria","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.vaccine.2026.128643_bb0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.15585\/mmwr.mm7319a4","article-title":"Progress toward poliomyelitis eradication\u2014worldwide, January 2022\u2013December 2023","volume":"73","author":"Geiger","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128643_bb0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.15585\/mmwr.mm7119a2","article-title":"Progress toward polio eradication\u2014worldwide, January 2020\u2013April 2022","volume":"71","author":"Rachlin","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"10.1016\/j.vaccine.2026.128643_bb0015","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128643_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz380","volume":"6","author":"Hu","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128643_bb0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/vaccines9060565","article-title":"Immunogenicity and safety of inactivated Sabin-strain polio vaccine \u201cPoliovacSin\u201d: clinical trials phase i and II","volume":"9","author":"Piniaeva","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128643_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/sji.70097","article-title":"Immunogenicity, safety and immune persistence of Sabin strain inactivated poliovirus vaccine: a phase III clinical trial","volume":"103","author":"Huang","year":"2026","journal-title":"Scand J Immunol"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128643_bb0035","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.vaccine.2021.02.073","article-title":"Immunogenicity and safety of Sabin-strain based inactivated poliovirus vaccine replacing Salk-strain based inactivated poliovirus vaccine: an innovative application of different strain-IPVs replacement","volume":"39","author":"Chen","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128643_bb0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: a progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128643_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128643_bb0050","unstructured":"PRISMA Statement. PRISMA statement website Available from: https:\/\/www.prisma-statement.org."},{"key":"10.1016\/j.vaccine.2026.128643_bb0055","unstructured":"The Cochrane collaboration. Review manager (RevMan) [computer program]. Version 5.4. London: The Cochrane Collaboration; 2020."},{"issue":"7414","key":"10.1016\/j.vaccine.2026.128643_bb0060","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128643_bb0065","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128643_bb0070","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.vaccine.2021.01.027","article-title":"Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for vaccination of a large population","volume":"39","author":"Jiang","year":"2021","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128643_bb0075","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/vaccines13111087","volume":"13","author":"Hu","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128643_bb0080","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2044255","article-title":"Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6\u00ae cell line: a phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age","volume":"18","author":"Ong-Lim","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128643_bb0085","series-title":"Polio eradication strategy 2022\u20132026: Delivering on a promise","author":"World Health Organization","year":"2021"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128643_bb0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/erv.11.51","article-title":"Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains","volume":"10","author":"Verdijk","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128643_bb0095","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.vaccine.2023.03.012","article-title":"Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: a phase IV observational study","volume":"41","author":"Chu","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128643_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102151","article-title":"Immune persistence of an inactivated poliovirus vaccine derived from the Sabin strain: a 10-year follow-up of a phase 3 study","volume":"64","author":"Ma","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.128643_bb0105","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1093\/infdis\/jiu222","article-title":"The new polio eradication end game: rationale and supporting evidence","volume":"210","author":"Sutter","year":"2014","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128643_bb0110","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol"},{"issue":"34","key":"10.1016\/j.vaccine.2026.128643_bb0115","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1016\/j.vaccine.2007.06.020","article-title":"Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns","volume":"25","author":"Leuridan","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128643_bb0120","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1080\/21645515.2021.1898306","article-title":"Surveillance of adverse events following introduction of Sabin-strain inactivated poliovirus vaccine and comparison with wild-strain IPV in Jiangsu, China","volume":"17","author":"Kang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128643_bb0125","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.vaccine.2023.01.048","article-title":"Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E. coli double mutant heat-labile toxin adjuvant in healthy adults: a phase 1 randomized study","volume":"41","author":"Erdem","year":"2023","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128643_bb0130","doi-asserted-by":"crossref","DOI":"10.2196\/12223","article-title":"Postvaccination fever response rates in children derived using the fever coach mobile app: a retrospective observational study","volume":"7","author":"Ahn","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"issue":"50","key":"10.1016\/j.vaccine.2026.128643_bb0135","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.46234\/ccdcw2024.261","article-title":"Surveillance for adverse events following immunization with domestic Sabin-strain inactivated poliovirus vaccine\u2014China, 2015\u20132022","volume":"6","author":"Fan","year":"2024","journal-title":"China CDC Wkly"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128643_bb0140","article-title":"Safety, immunogenicity and lot-to-lot consistency of Sabin-strain inactivated poliovirus vaccine in 2-month-old infants: a double-blind randomized phase III trial","volume":"10","author":"Zheng","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128643_bb0145","article-title":"Polio outbreaks due to vaccine-derived viruses demand a re-definition of vaccine safety","author":"John","year":"2025","journal-title":"Lancet Microbe"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128643_bb0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"Pt 3","key":"10.1016\/j.vaccine.2026.128643_bb0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1099\/vir.0.036988-0","article-title":"The polio-eradication programme and issues of the end game","volume":"93","author":"Minor","year":"2012","journal-title":"J Gen Virol"},{"issue":"41","key":"10.1016\/j.vaccine.2026.128643_bb0160","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128643_bb0165","doi-asserted-by":"crossref","first-page":"11970","DOI":"10.1038\/s41598-019-48534-1","article-title":"Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test","volume":"9","author":"Arita","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128643_bb0170","article-title":"Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses","volume":"300","author":"Liu","year":"2021","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128643_bb0175","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12985-025-02977-3","article-title":"Immunogenicity and safety of polio vaccines in infants: a systematic review of randomized clinical trials","volume":"22","author":"Terekhov","year":"2025","journal-title":"Virol J"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128643_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2018.1489188","article-title":"Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: a systematic review and meta-analysis","volume":"14","author":"Tang","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128643_bb0185","unstructured":"World Health Organization. Polio vaccines: WHO position paper \u2013 June 2022. Wkly Epidemiol Rec 2022;97(25):277\u2013300. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-WER9725-277-300."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:15:49Z","timestamp":1778739349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["S0264410X26004512"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128643","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of Sabin-strain inactivated poliovirus vaccine in infants: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128643"}}